从黄皮核中提取分离和结构鉴定，得到单体黄皮新肉桂酰胺B（lansiumamide B，LB），通过细胞和小鼠实验验证，LB具有较强的体内外降脂效果。结果如下：LB能高效抑制人体中重要的三种消化酶α-淀粉酶、α-葡萄糖苷酶和胰脂肪酶的活性，IC50分别为（18.43±1.49）μg/mL、（15.27±0.37）μg/mL和（0.16±0.01）mg/mL；作用于油酸（OA）诱导的高脂HepG2细胞，浓度为5 μg/mL时，甘油三酯（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、谷丙转氨酶（ALT）、谷草转氨酶（AST）、丙二醛（MDA）分别降低了30.77%、30.00%、58.33%、39.97%、38.84%和43.90%，高密度脂蛋白胆固醇（HDL-C）、过氧化氢酶（CAT）以及低密度脂蛋白受体（LDLR）分别提高了83.33%、253.37%%、60.97%；LB饲喂于高脂小鼠6 周后，体重都有明显的降低，与高脂组有明显差异（p ＜ 0.05）；血清中的血脂四项，给药组剂量为60 mg/kg时，TC、TG和LDL-C分别降低了29.18%、23.69%、70.27%，HDL-C升高了50.51%，说明高脂小鼠的体重和血脂四项指标都得到了很好的控制。本工作初步表明LB具有较好的细胞和活体降血脂作用，是一种潜在的膳食降脂成分。

Lansiumamide B (LB) was obtained by isolation and structural identification of the seeds of wampee. LB was verified by cell and mouse experiments to have strong lipid-lowering effect in vivo and in vitro. The results were as follows: LB could effectively inhibit the activities of α-amylase, α-glucosidase and pancreatic lipase with IC50 values of (18.43±1.49) μg/mL, (15.27±0.37) μg/mL and (0.16±0.01) mg/mL, respectively. When the concentration was 5 μg/mL, triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) and malondialdehyde (MDA) decreased by 30.77%, 30.00%, 58.33%, 39.97%, 38.84% and 43.90%, respectively. High density lipoprotein cholesterol (HDL-C), catalase (CAT) and low density lipoprotein receptor (LDLR) increased by 83.33%, 253.37% and 60.97%, respectively. After 6 weeks of feeding in LB mice with high fat, the body weight was significantly decreased, which was significantly different from that of high fat group (p < 0.05). TC, TG and LDL-C were decreased by 29.18%, 23.69% and 70.27%, respectively, and HDL-C was increased by 50.51% when the dose of 60 mg/kg group was given. The results showed that the four indexes of body weight and blood lipid of high-fat mice were well controlled. These results suggest that LB is a potential dietary lipid-lowering component with good cell and in vivo lipid-lowering effects.